Business
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the secon
About this update from Fulcrum Therapeutics, Inc.
[{"type":"image","alt":"Fulcrum Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Fulcrum Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/b2436aacd8d6614fd2b1c157e4f5cc27"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n.X.8ZqQNvv9C0Ig4vezOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b2436aacd8d6614fd2b1c157e4f5cc27","width":300,"height":73}},"lazy":false},{"type":"text","content":"― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―","length":137,"tagName":"p"},{"type":"text","content":"― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ―","length":281,"tagName":"p"},{"type":"text","content":"― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ―","length":96,"tagName":"p"},{"type":"text","content":"― Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ―","length":110,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quarter and full year 2025 and provided a business update.","length":366,"tagName":"p"},{"type":"text","content":"“Building on the previously reported interim data presented in December at ASH, the positive 12-week data from the complete 20 mg cohort of the PIONEER trial reinforce our conviction in pociredir’s potential to address the underlying biology of sickle cell disease,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer. “The magnitude of HbF induction, progression toward pan-cellular distribution, and improvements in markers of hemolysis and anemia observed to date position us well as we prepare for discussions with the FDA regarding the d...